[{"address1": "Wagistrasse 14", "city": "Schlieren", "zip": "8952", "country": "Switzerland", "phone": "41 44 755 77 00", "fax": "41 44 755 77 07", "website": "https://www.molecularpartners.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.", "fullTimeEmployees": 167, "companyOfficers": [{"maxAge": 1, "name": "Dr. Patrick  Amstutz Ph.D.", "age": 49, "title": "Co-Founder, CEO, Member of Management Board & Director", "yearBorn": 1975, "fiscalYear": 2023, "totalPay": 731292, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael Tobias Stumpp Ph.D.", "age": 52, "title": "Co-Founder, Executive VP of Projects & Member of Management Board", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Robert  Hendriks", "title": "Senior VP of Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Alexander  Zurcher", "age": 49, "title": "COO & Member of Management Board", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Renate  Gloggner", "age": 54, "title": "Executive VP of People & Community and Member of Management Board", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel  Steiner Ph.D.", "title": "Senior Vice President of Research & Technology", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Seth D. Lewis", "title": "Senior Vice President of Investor Relations, Communications & Strategy", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Pitzner", "title": "General Counsel, Compliance Officer, Senior VP Legal & Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pamela A. Trail Ph.D.", "age": 68, "title": "Strategic Consultant", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Goubier D.V.M., Ph.D.", "title": "Senior Vice President of Research & Early Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.96, "open": 5.1, "dayLow": 4.97, "dayHigh": 4.97, "regularMarketPreviousClose": 4.96, "regularMarketOpen": 5.1, "regularMarketDayLow": 4.97, "regularMarketDayHigh": 4.97, "beta": 0.537, "forwardPE": -3.0304878, "volume": 19, "regularMarketVolume": 19, "averageVolume": 13541, "averageVolume10days": 3040, "averageDailyVolume10Day": 3040, "marketCap": 183209600, "fiftyTwoWeekLow": 3.32, "fiftyTwoWeekHigh": 12.7, "priceToSalesTrailing12Months": 30.52476, "fiftyDayAverage": 5.35194, "twoHundredDayAverage": 5.48602, "currency": "USD", "enterpriseValue": 24103364, "floatShares": 6460223, "sharesOutstanding": 36863100, "sharesShort": 44777, "sharesShortPriorMonth": 48786, "sharesShortPreviousMonthDate": 1734048000, "dateShortInterest": 1736899200, "sharesPercentSharesOut": 0.0011999999, "heldPercentInstitutions": 0.053049996, "shortRatio": 5.49, "shortPercentOfFloat": 0.0017, "impliedSharesOutstanding": 37422200, "bookValue": 4.181, "priceToBook": 1.1887107, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -62591000, "trailingEps": -2.1, "forwardEps": -1.84, "enterpriseToRevenue": 4.016, "enterpriseToEbitda": -0.388, "52WeekChange": 0.0804348, "SandP52WeekChange": 0.21027291, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "MOLN", "underlyingSymbol": "MOLN", "shortName": "Molecular Partners AG", "longName": "Molecular Partners AG", "firstTradeDateEpochUtc": 1623850200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "3b1227e2-09aa-3330-8282-b0e2c7493dad", "messageBoardId": "finmb_32677064", "gmtOffSetMilliseconds": -18000000, "currentPrice": 4.97, "targetHighPrice": 16.834692, "targetLowPrice": 4.973586, "targetMeanPrice": 10.442802, "targetMedianPrice": 9.520142, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 143618000, "totalCashPerShare": 4.327, "ebitda": -62162000, "totalDebt": 2747000, "quickRatio": 14.081, "currentRatio": 14.33, "totalRevenue": 6002000, "debtToEquity": 1.979, "revenuePerShare": 0.182, "returnOnAssets": -0.21174, "returnOnEquity": -0.37369, "grossProfits": -43963000, "freeCashflow": -38458248, "operatingCashflow": -62041000, "revenueGrowth": -0.732, "operatingMargins": -21.42291, "financialCurrency": "CHF", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]